You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 9,429,574

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,429,574
Title:Cancer therapies and methods
Abstract: The present invention provides an inhibitor of the ubiquitin-proteasome system for use in treating cancer in a patient, wherein the patient is assessed to establish that the cancer is associated with cells in which the functional activity of SMARCB1 is low or absent. In one embodiment, the patient has, or is suspected of having, breast cancer, an atypical teratoid rhabdoid tumor (AT/RT) and/or a malignant rhabdoid tumor (MRT). In one embodiment, the proteasome inhibitor is Bortezomib. Further aspects of the invention provide related uses and methods.
Inventor(s): Nuber; Ulrike (Malmo, SE)
Application Number:13/683,179
Patent Claims:see list of patent claims

Details for Patent 9,429,574

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial 2031-05-16 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial 2031-05-16 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial 2031-05-16 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.